Taylor Ortiz, MD

Oncologist, fmr Harvard Med, Dana-Farber/MGH, Franciscan Onc Medical Director, Clinical Trials. Views are my own.

[Taylor Ortiz, MD @tmortiz]

@edgarwright What a great night with a cheering audience at @AMCTheatres Boston Common. Had to do with a paper tie, though

[Patrick Forde @FordePatrick]

Interesting, inadvertent data release suggests atezo-tira combo trending in right direction. Although the OS in control of ~16m is not stellar. Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer https://t.co/uWxDEKFbAD

[Paolo Tarantino @PTarantinoMD]

Consistent with the PACE trial, the PALMIRA randomized phase 2 trial showed no benefit in terms of PFS or OS with the use of palbociclib beyond progression to 1L ET+palbo.

Patients progressing on 1L palbo should not receive further exposure to palbo. #ASCO23

[JAMA Oncology @JAMAOnc]

Study of patients with #NSCLC showed no survival difference between 2-yr fixed duration vs indefinite #immunotherapy, suggesting that IO can be d/c at 2 yrs.

@PennCancer @flatironhealth @lovasunMD @Ron_cology @CharuAggarwalMD #ASCO23

https://t.co/EWyneghc8a

[Toni Choueiri, MD @DrChoueiri]

Phenomonal work by @Dolmos77
#BRCA mutated #ProstateCancer ➡️ worse outcomes (regardless of germline/somatic origin)
Early screening for #HRR mutations is crucial!
@OncoAlert #ASCO23

[Krishan Jethwa @KrishanJethwa]

🚨🚨🚨 PROSPECT Trial has landed!

Congratulations to all investigators, @ALLIANCE_org, for this important trial!

This study is important, will shape, and SHOULD alter practice for OPERATIVELY managed patients with favorable risk LA- rectal cancer.

https://t.co/e8B4m9mIrS

[Paolo Tarantino @PTarantinoMD]

With #ASCO23-week officially here, it is time for a #top10 list of breast abstracts! Several potentially practice-changing trials to be presented during the congress. Take a look, share if you found it useful and feel free to recommend additional impactful abstracts to add! #bcsm

[Balazs Halmos @BalazsHalmosMD]

#ASCO23 ADAURAble results!

How it started How it is going
👇 👇

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

🔗KEYNOTE-789: P-chemo + Pembro in Osi resistant EGFR-mutant NSCLC
▪️PFS & OS ❌
▫️PD-L1 not a biomarker here
Again, a negative trial in this setting.
Bispecific mAb (amivantamab), ADC (E.g. Patritumab) and TKIs are the ways to follow targeting EGFR resistance
#ASCO23

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

👁️‍🗨️Sunvozertinib (DZD9008) in EGFR exon20ins from the Ph2 WU-KONG6
◾️ORR by BICR 60.8%
◾️ORR in baseline brain 48.5%
◾️mDoR NR
◾️Safety consistent w/ previous TKIs
🧿 30 different exon20ins subtypes were enrolled (…the need of NGS to identify all of these pts)
#ASCO23

[Toni Choueiri, MD @DrChoueiri]

1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to @montypal, SC members, @roche, our patients, = for this phenomenal job.
https://t.co/p7hYD4snXA

[Pradeep Natarajan @pnatarajanmd]

Super cool observation that a monogenic mechanism of longer telomeres yields familial clonal hematopoiesis of indeterminate potential. https://t.co/0S21vsUdBC @NEJM

This is super cool bc it's not the expectation as @ginakolata @nytimes explains (https://t.co/QhNxvZ2IJq)

🧵👇

[Nancy Lin, MD @nlinmd]

Can ADCs work in the CNS?? Evidence of clinical efficacy of TDXd in a real-world case series of pts with HER2+ leptomeningeal disease. @LauraAtHome @darioT_ @drsarahsam

[The ASCO Post @ASCOPost]

Researchers Find No Significant Differences in Overall Survival Among Patients With Platinum-Sensitive Recurrent Ovarian Cancer Who Received Niraparib Maintenance Therapy vs Placebo https://t.co/fuSZQGLKgI #gyncsm #OvarianCancer #oncology #sgo2023 #SGO23

[Dr Riyaz Shah @DrRiyazShah]

CM816; This is a killer slide. We already knew of the surgical outcome improvements thanks to @DoctorJSpicer . Not only does NAC+IO achieve that but look at the halving of distant recurrence and esp brain mets. Amazing. #ELCC23.

[Taylor Ortiz, MD @tmortiz]

@loconte Congrats to you!

[Toni Choueiri, MD @DrChoueiri]

Screening and early detection are common sense to detecting cancer earlier and saving lives. Please amplify!

@ASCO @jrgralow @CliffordHudis @ASCOPost @JCO_ASCO @ASCOPres @OncoAlert @AmericanCancer @AmerCancerCEO @DanaFarber @DanaFarber

[Taylor Ortiz, MD @tmortiz]

@ASCO @jrgralow Very frustrating to hear this. Link to the court's decision?

[Taylor Ortiz, MD @tmortiz]

https://t.co/NRabR93kHy

[Richard Dunne, MD @DrR_DUNNE]

RCT shows lowest dose olanzapine:

✅increases weight
✅increases caloric intake
✅improves nutr. status
✅improves QOL
✅improves appetite
✅ lowers chemo toxicity
✅improved RDI
✅20% pts able to incr. chemo dose!!
✅has almost no side efx

Too good to be true?

[Richard Dunne, MD @DrR_DUNNE]

RCT shows lowest dose olanzapine:

✅increases weight
✅increases caloric intake
✅improves nutr. status
✅improves QOL
✅improves appetite
✅ lowers chemo toxicity
✅improved RDI
✅20% pts able to incr. chemo dose!!
✅has almost no side efx

Too good to be true?